liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Expression of FXYD3 Protein in Relation to Biological and Clinicopathological Variables in Colorectal Cancers
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Health Sciences.
Östergötlands Läns Landsting, Centre of Surgery and Oncology, Department of Surgery in Östergötland. (Landstinget i Östergötland)
Univ Heidelberg, Inst Clin Radiol and Nucl Med, Univ Hosp Mannheim, Heidelberg, Germany.
Show others and affiliations
2009 (English)In: Chemotherapy, ISSN 0009-3157, E-ISSN 1421-9794, Vol. 55, no 6, 407-413 p.Article in journal (Refereed) Published
Abstract [en]

Background: FXYD3 is up-/down-regulated in different types of cancers. We examined FXYD3 expression in colorectal cancers and its relationship to biological and clinicopathological variables. Patients and Methods: Expression of FXYD3 protein was immunohistochemically examined in distant normal mucosa (n = 34), adjacent normal mucosa (n = 72), primary tumour (n = 150) and lymph node metastasis (n = 35) from colorectal cancer patients. Results: FXYD3 was highly expressed in primary tumour compared to adjacent normal mucosa (p = 0.02). FXYD3 was or tended to be positively related to the expression of ras (p = 0.02), p53 (p = 0.06), legumain (p = 0.02) and proliferating cell nuclear antigen (p = 0.03). Moreover, there was a higher frequency of strong FXYD3 expression in Dukes A-C tumours than in D tumours (p = 0.04). The strong FXYD3 expression tended to predict worse survival in the patients with Dukes A + B tumour (p = 0.07), while there was no such tendency in the patients with Dukes C + D tumour (p = 0.94). The tumours located in the colon had a higher degree of FXYD3 expression than the tumours located in the rectum (p = 0.05). Conclusion: The FXYD3 was associated with certain biological variables and may be involved in the development of the relative earlier stages of colorectal cancers.

Place, publisher, year, edition, pages
2009. Vol. 55, no 6, 407-413 p.
Keyword [en]
Colorectal cancer; FXYD3; Immunohistochemistry
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-52911DOI: 10.1159/000263227OAI: oai:DiVA.org:liu-52911DiVA: diva2:285748
Available from: 2010-01-13 Created: 2010-01-12 Last updated: 2017-12-12

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Widegren, EmmaÖnnesjö, SofiaSun, Xiao-Feng

Search in DiVA

By author/editor
Widegren, EmmaÖnnesjö, SofiaSun, Xiao-Feng
By organisation
Department of Clinical and Experimental MedicineFaculty of Health SciencesDepartment of Surgery in ÖstergötlandOncology Department of Oncology UHL
In the same journal
Chemotherapy
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 68 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf